Literature DB >> 22921595

Epigenetics advancing personalized nanomedicine in cancer therapy.

Shujun Liu1.   

Abstract

Personalized medicine aims to deliver the right drug to a right patient at the right time. It offers unique opportunities to integrate new technologies and concepts to disease prognosis, diagnosis and therapeutics. While selective personalized therapies are conceptually impressive, the majority of cancer therapies have dismal outcome. Such therapeutic failure could result from no response, drug resistance, disease relapse or severe side effect from improper drug delivery. Nanomedicine, the application of nanotechnology in medicine, has a potential to advance the identification of diagnostic and prognostic biomarkers and the delivery of right drug to disease sites. Epigenetic aberrations dynamically contribute to cancer pathogenesis. Given the individualized traits of epigenetic biomarkers, epigenetic considerations would significantly refine personalized nanomedicine. This review aims to dissect the interface of personalized medicine with nanomedicine and epigenetics. I will outline the progress and highlight challenges and areas that can be further explored perfecting the personalized health care.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22921595      PMCID: PMC3477272          DOI: 10.1016/j.addr.2012.08.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  168 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 2.  Clinical proteomics: translating benchside promise into bedside reality.

Authors:  Emanuel F Petricoin; Kathryn C Zoon; Elise C Kohn; J Carl Barrett; Lance A Liotta
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

3.  Azacitidine.

Authors:  Jean-Pierre J Issa; Hagop M Kantarjian; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 4.  Applications of nanobiotechnology in clinical diagnostics.

Authors:  Kewal K Jain
Journal:  Clin Chem       Date:  2007-09-21       Impact factor: 8.327

5.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  Refocusing the war on cancer: the critical role of personalized treatment.

Authors:  Anil Potti; Richard L Schilsky; Joseph R Nevins
Journal:  Sci Transl Med       Date:  2010-04-21       Impact factor: 17.956

8.  Matrix-insensitive protein assays push the limits of biosensors in medicine.

Authors:  Richard S Gaster; Drew A Hall; Carsten H Nielsen; Sebastian J Osterfeld; Heng Yu; Kathleen E Mach; Robert J Wilson; Boris Murmann; Joseph C Liao; Sanjiv S Gambhir; Shan X Wang
Journal:  Nat Med       Date:  2009-10-11       Impact factor: 53.440

9.  Leukemia following chemotherapy for breast cancer.

Authors:  R E Curtis; J D Boice; W C Moloney; L G Ries; J T Flannery
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

10.  Incidence of acute myeloid leukemia after breast cancer.

Authors:  Caterina Giovanna Valentini; Luana Fianchi; Maria Teresa Voso; Morena Caira; Giuseppe Leone; Livio Pagano
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-22       Impact factor: 2.576

View more
  11 in total

Review 1.  -Omic and Electronic Health Record Big Data Analytics for Precision Medicine.

Authors:  Po-Yen Wu; Chih-Wen Cheng; Chanchala D Kaddi; Janani Venugopalan; Ryan Hoffman; May D Wang
Journal:  IEEE Trans Biomed Eng       Date:  2016-10-10       Impact factor: 4.538

2.  Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

Authors:  Narasimha M Midde; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-09-10

Review 3.  Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals.

Authors:  Aamir Ahmad; Yiwei Li; Bin Bao; Dejuan Kong; Fazlul H Sarkar
Journal:  Mol Nutr Food Res       Date:  2013-11-24       Impact factor: 5.914

4.  PLGA-Loaded Gold-Nanoparticles Precipitated with Quercetin Downregulate HDAC-Akt Activities Controlling Proliferation and Activate p53-ROS Crosstalk to Induce Apoptosis in Hepatocarcinoma Cells.

Authors:  Kausik Bishayee; Anisur Rahman Khuda-Bukhsh; Sung-Oh Huh
Journal:  Mol Cells       Date:  2015-05-07       Impact factor: 5.034

Review 5.  Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy.

Authors:  Jing Zhang; Hua Tang; Zefa Liu; Baoan Chen
Journal:  Int J Nanomedicine       Date:  2017-11-28

6.  Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.

Authors:  F Yan; N Shen; J X Pang; Y W Zhang; E Y Rao; A M Bode; A Al-Kali; D E Zhang; M R Litzow; B Li; S J Liu
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

Review 7.  Epigenetics in cancer therapy and nanomedicine.

Authors:  Annalisa Roberti; Adolfo F Valdes; Ramón Torrecillas; Mario F Fraga; Agustin F Fernandez
Journal:  Clin Epigenetics       Date:  2019-05-16       Impact factor: 6.551

Review 8.  Nanomaterials for Protein Delivery in Anticancer Applications.

Authors:  Anne Yau; Jinhyung Lee; Yupeng Chen
Journal:  Pharmaceutics       Date:  2021-01-25       Impact factor: 6.321

Review 9.  An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality.

Authors:  Steffen Mueller; Gail Dennison; Shujun Liu
Journal:  Int J Environ Res Public Health       Date:  2021-06-28       Impact factor: 3.390

10.  A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis.

Authors:  Na Shen; Fei Yan; Jiuxia Pang; Lai-Chu Wu; Aref Al-Kali; Mark R Litzow; Shujun Liu
Journal:  Oncotarget       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.